User profiles for R. J. Edwards

Richard J Edwards

Oceans Institute, University of Western Australia
Verified email at uwa.edu.au
Cited by 2927

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human micro-somal protein and …

…, AR Boobis, DJ Carlile, RJ Edwards… - Current drug …, 2007 - ingentaconnect.com
Reported predictions of human in vivo hepatic clearance from in vitro data have used a variety
of values for the scaling factors human microsomal protein (MPPGL) and hepatocellularity …

Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review

…, P McColgan, P Bentley, RJ Edwards… - British journal of …, 2012 - Wiley Online Library
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Stroke is the largest single cause of
disability in the UK. While tests based upon biomarkers have been around for decades, …

[HTML][HTML] Recent progress and considerations for AAV gene therapies targeting the central nervous system

EA Lykken, C Shyng, RJ Edwards, A Rozenberg… - Journal of …, 2018 - Springer
Background Neurodevelopmental disorders, as a class of diseases, have been particularly
difficult to treat even when the underlying cause(s), such as genetic alterations, are …

[HTML][HTML] Randomized trial of preventive angioplasty in myocardial infarction

…, NJ Wald, AJ Chase, RJ Edwards… - … England Journal of …, 2013 - Mass Medical Soc
Background In acute ST-segment elevation myocardial infarction (STEMI), the use of
percutaneous coronary intervention (PCI) to treat the artery responsible for the infarct (infarct, or …

[HTML][HTML] Percutaneous revascularization for ischemic left ventricular dysfunction

…, S Arnold, LJ Dixon, RJ Edwards… - … England Journal of …, 2022 - Mass Medical Soc
Background Whether revascularization by percutaneous coronary intervention (PCI) can
improve event-free survival and left ventricular function in patients with severe ischemic left …

Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity

…, K Manne, D Li, K Wiehe, KO Saunders, RJ Edwards… - Science, 2021 - science.org
INTRODUCTION Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
have been circulating worldwide since the beginning of the pandemic. Some are termed …

[HTML][HTML] Controlling the SARS-CoV-2 spike glycoprotein conformation

R Henderson, RJ Edwards, K Mansouri… - Nature structural & …, 2020 - nature.com
The coronavirus (CoV) spike (S) protein, involved in viral–host cell fusion, is the primary
immunogenic target for virus neutralization and the current focus of many vaccine design efforts. …

[PDF][PDF] D614G spike mutation increases SARS CoV-2 susceptibility to neutralization

…, H Hornsby, R Brown, CC LaBranche, RJ Edwards… - Cell host & …, 2021 - cell.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein acquired
a D614G mutation early in the pandemic that confers greater infectivity and is now the …

[PDF][PDF] In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

D Li, RJ Edwards, K Manne, DR Martinez, A Schäfer… - Cell, 2021 - cell.com
SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding
SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated …

[HTML][HTML] Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

…, R Parks, DR Martinez, D Li, H Chen, RJ Edwards… - Nature, 2021 - nature.com
Betacoronaviruses caused the outbreaks of severe acute respiratory syndrome (SARS) and
Middle East respiratory syndrome, as well as the current pandemic of SARS coronavirus 2 (…